YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Investing.com -- Raymond James has identified its top stock picks in the healthcare sector, highlighting companies with upcoming clinical trial results and promising drug development programs. The firm's Analyst Current Favorites list feat…
Trevi Therapeutics has delivered very strong long term gains, yet the stock now screens as expensive on broad valuation checks. This raises questions about how much of the story is already in the price. The stock has returned roughly 10x o…
Initiated Phase 3 OCEAN-1 trial for patients with idiopathic pulmonary fibrosis-related chronic cough in the second quarter; Phase 3 OCEAN-2 trial expected to initiate in the third quarter of 2026 Initiated Phase 2b LAKE trial for patients…
NEW HAVEN, Conn., July 28, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough…
Trevi Therapeutics grew its share prices by 9.85 percent on Friday to finish at $19.07 apiece, after management underscored strong clinical trial results from its treatment candidate for chronic cough. Speaking at a three-day conference in…
In trading on Tuesday, the iShares US Pharmaceuticals ETF is outperforming other ETFs, up about 3.1% on the day. Components of that ETF showing particular strength include shares of Crinetics Pharmaceuticals, up about 98.8% and shares of T…
NEW HAVEN, Conn., June 17, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough…
Pivotal bioVenture Partners Investment Advisor increased its position in Trevi Therapeutics(NASDAQ:TRVI) during the first quarter, acquiring 296,944 shares in an estimated $3.32 million trade based on average quarterly pricing, according t…
[Financial market sector Healthcare on blue finance background from graphs, charts. 3D render] Vladimir Zakharov A screen of U.S. healthcare stocks with market capitalizations between $300M and $2B highlights several small-cap companies, i…
NEW HAVEN, Conn., April 23, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic coug…
NEW HAVEN, Conn., April 16, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic coug…
NEW HAVEN, Conn., April 01, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic coug…
On February 17, 2026, Acorn Capital Advisors reported selling 225,000 shares of Terns Pharmaceuticals(NASDAQ:TERN), an estimated $5.20 million trade based on quarterly average pricing. What happened According to a filing with the Securitie…
(RTTNews) - Trevi Therapeutics, Inc. (TRVI), a clinical-stage biopharmaceutical company, reported fourth-quarter and full-year 2025 financial results reflecting a narrower loss. In addition, the firm provided updates on the trials of its l…
The following companies are expected to report earnings after hours on 03/17/2026. Visit our Earnings Calendar for a full list of expected earnings releases. lululemon athletica inc. (LULU)is reporting for the quarter ending January 31, 20…
The Company will conduct two Phase 3 clinical trials of nalbuphine ER for the treatment of patients with IPF-related chronic cough First pivotal trial is on track to initiate in the second quarter of 2026, with the second pivotal trial exp…
NEW HAVEN, Conn., January 14, 2026--(BUSINESS WIRE)--BioCT, Connecticut’s life sciences trade organization, is pleased to announce the appointment of four distinguished executives to its Board of Directors. The organization has elected Ran…
Rising 2026 growth chart emerging over an industrial cityscape. Key Points Small-cap stocks are regaining momentum as rate cuts and the end of quantitative tightening drive a renewed risk-on environment. MarketBeat’s top-rated small-cap na…
Trevi Therapeutics, Inc. (NASDAQ:TRVI) is one of the 12 best multibagger stocks to buy heading into 2026.Trevi Therapeutics (TRVI) Targets Next Phase of Growth with Leadership Change Copyright: djoronimo / 123RF Stock Photo On December 4,…
Key Points Boston-based MPM BioImpact sold 1.3 million shares of MBX Biosciences worth an estimated $14.8 million in the third quarter. The move marked a full exit for MPM BioImpact, which reported holding no shares of MBX at the end of th…
Key Points Boston-based MPM Bioimpact sold 313,571 shares of MoonLake Immunotherapeutics in the third quarter, reducing the position by about $14.8 million. The move marked a full exit for MPM, which reported holding no MLTX shares at quar…
Key Points Boston-based MPM Bioimpact sold 313,571 shares of MoonLake Immunotherapeutics in the third quarter, reducing the position by about $14.8 million. The move marked a full exit for MPM, which reported holding no MLTX shares at quar…
Key Points Boston-based MPM Bioimpact sold 313,571 shares of MoonLake Immunotherapeutics in the third quarter, reducing the position by about $14.8 million. The move marked a full exit for MPM, which reported holding no MLTX shares at quar…
Key Points Boston-based MPM BioImpact sold 1.3 million shares of MBX Biosciences worth an estimated $14.8 million in the third quarter. The move marked a full exit for MPM BioImpact, which reported holding no shares of MBX at the end of th…
Key Points Boston-based MPM BioImpact sold 428,975 shares of Crinetics Pharmaceuticals worth about $12.3 million in the third quarter. The move marked a full exit for MPM, which reported holding no shares of CRNX at quarter-end. The positi…
Earnings Call Insights: Trevi Therapeutics (TRVI) Q3 2025 MANAGEMENT VIEW * Jennifer Good, Co-Founder, CEO, President, and Interim Principal Financial Officer, highlighted, "The first half of this year was a major inflection point for Trev…
The following companies are expected to report earnings after hours on 11/13/2025. Visit our Earnings Calendar for a full list of expected earnings releases. Applied Materials, Inc. (AMAT)is reporting for the quarter ending October 31, 202…
NRG Energy Inc (Symbol: NRG) has been named as a Top 10 dividend paying utility stock, according to Dividend Channel, which published its weekly ''DividendRank'' report. The report noted that among utilities, NRG shares displayed both attr…
Trevi Therapeutics Inc. (NASDAQ:TRVI) is one of the best multibagger stocks to invest in right now. On August 21, Morgan Stanley’s Judah Frommer initiated coverage of the stock with an Overweight rating and an $18 price target. The Overwei…
[Wall street] Trevi Therapeutics (NASDAQ:TRVI [https://seekingalpha.com/symbol/TRVI]), a clinical-stage biopharma focused on treatments for cough conditions, traded higher on Wednesday after B. Riley, with a Buy rating, reportedly highligh…
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Morgan Stanley upgraded HP Enterprise(HPE)…
Earnings Call Insights: Trevi Therapeutics (TRVI) Q2 2025 MANAGEMENT VIEW * Jennifer L. Good, CEO, described the first half of the year as a major inflection point for Trevi, highlighting positive data from the CORAL trial in idiopathic pu…
[Business and stock exchange data on the screen.] Torsten Asmus Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next w…
PHILADELPHIA, June 26, 2025 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Trevi Therapeutics, Inc. (NASDAQ: TRVI) (“Trevi”) on behalf of the company’s long-term investors. Click here for additional information: htt…
(RTTNews) - Trevi Therapeutics, Inc. (TRVI), a clinical-stage biopharmaceutical company focused on developing Haduvio - oral nalbuphine ER for chronic cough in idiopathic pulmonary fibrosis - IPF and refractory chronic cough - RCC patients…
* Clinical-stage biopharmaceutical company Trevi Therapeutics (NASDAQ:TRVI [https://seekingalpha.com/symbol/TRVI]) priced [https://seekingalpha.com/pr/20125587-trevi-therapeutics-announces-pricing-of-100-million-underwritten-offering-of-co…